Prostate Centre news

Abiraterone refused funding on the NHS by NICE

February 2, 2012

The Prostate Centre would like to express disappointment that the appraisal consultation document published by NICE does not recommend abiraterone for use in the NHS.

The available evidence confirms that this drug is both safe and effective and addresses an unmet clinical need for patients with advanced prostate cancer after chemotherapy. As a consequence of this decision many men will now die sooner than they otherwise would.

We would recommend that all the relevant parties, including NICE, work together to provide a solution that allows patients access to this important new drug.

Ref: NEJM 2011:364(21);1995-2005

< Back to article list